Patent intelligence · US
US 12091386
D-amphetamine compounds, compositions, and processes for making and using the same
D-amphetamine compounds, compositions, and processes for making and using the same
Patent details — US 12091386
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2024
- Expiration
- Sep 12, 2044
- Applicant
- Zevra Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/4458, A61K31/4545, A61K47/55
Quick answer
US 12091386 (D-amphetamine compounds, compositions, and processes for making and using the same) is held by Zevra Therapeutics, Inc.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Zevra Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/4458, A61K31/4545, A61K47/55, A61K9/0019, A61K9/0043
More from Zevra Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12251445
Gamma-hydroxybutyrate delivering compounds and processes for making and using them
granted -
US 12076316
Levorphanol prodrugs and processes for making and using them
granted -
US 12012384
Dextrorphan prodrugs and processes for making and using them
granted -
US 11938125
Use of Hsp70 as a regulator of enzymatic activity
granted
Frequently asked questions
What is US patent 12091386?
US 12091386 (D-amphetamine compounds, compositions, and processes for making and using the same) is held by Zevra Therapeutics, Inc.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12091386?
Zevra Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12091386 expire?
Our index shows an expiration date of Sep 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.